Loading...
Publication
Canábis medicinal para o tratamento da dor crónica
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| Projeto de pós-graduação_39641 | 958.11 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
A dor crónica é uma condição complexa e debilitante que afeta milhões de pessoas em todo o mundo, comprometendo significativamente a qualidade de vida dos indivíduos afetados. A abordagem convencional no tratamento deste tipo de dor baseia-se frequentemente no uso de analgésicos opioides e anti-inflamatórios que, embora eficazes a curto prazo, apresentam uma série de limitações, incluindo o risco de dependência, efeitos secundários graves e, em alguns casos, a ineficácia na redução da dor. Neste contexto, a canábis medicinal tem surgido como uma alternativa terapêutica promissora, dada a sua potencial capacidade de aliviar a dor de forma eficaz e com um perfil de segurança favorável. Este trabalho tem como objetivo fazer uma revisão atual da literatura existente sobre os efeitos da canábis medicinal no tratamento da dor crónica. A canábis contém vários compostos ativos, sendo os principais canabinoides o delta-9-tetrahidrocanabinol e o canabidiol, que interagem com o sistema endocanabinoide do organismo, tendo assim a capacidade de modular a resposta à dor. As evidências clínicas têm demonstrado que este componente pode reduzir significativamente a intensidade da dor crónica, particularmente em casos de neuropatia, esclerose múltipla, artrite e outras condições dolorosas resistentes ao tratamento convencional. Em Portugal, a canábis foi legalizada em 2018 para determinadas condições médicas, incluindo a dor crónica, mas o seu uso permanece restrito e altamente regulado.
Chronic pain is a complex and debilitating condition that affects millions of people worldwide, significantly compromising the quality of life of those affected. The conventional approach to treating this type of pain often relies on the use of opioid analgesics and anti-inflammatory drugs, which, although effective in the short term, present several limitations, including the risk of dependence, severe side effects, and, in some cases, ineffectiveness in reducing pain. In this context, medical cannabis has emerged as a promising therapeutic alternative, given its potential ability to relieve pain effectively with a favorable safety profile. This work aims to provide an up-to-date review of the existing literature on the effects of medical cannabis in the treatment of chronic pain. Cannabis contains several active compounds, with the main cannabinoids being delta-9-tetrahydrocannabinol and cannabidiol, which interact with the body's endocannabinoid system, thereby modulating the pain response. Clinical evidence has shown that these components can significantly reduce the intensity of chronic pain, particularly in cases of neuropathy, multiple sclerosis, arthritis, and other painful conditions resistant to conventional treatment. In Portugal, cannabis was legalized in 2018 for certain medical conditions, including chronic pain, but its use remains restricted and highly regulated.
Chronic pain is a complex and debilitating condition that affects millions of people worldwide, significantly compromising the quality of life of those affected. The conventional approach to treating this type of pain often relies on the use of opioid analgesics and anti-inflammatory drugs, which, although effective in the short term, present several limitations, including the risk of dependence, severe side effects, and, in some cases, ineffectiveness in reducing pain. In this context, medical cannabis has emerged as a promising therapeutic alternative, given its potential ability to relieve pain effectively with a favorable safety profile. This work aims to provide an up-to-date review of the existing literature on the effects of medical cannabis in the treatment of chronic pain. Cannabis contains several active compounds, with the main cannabinoids being delta-9-tetrahydrocannabinol and cannabidiol, which interact with the body's endocannabinoid system, thereby modulating the pain response. Clinical evidence has shown that these components can significantly reduce the intensity of chronic pain, particularly in cases of neuropathy, multiple sclerosis, arthritis, and other painful conditions resistant to conventional treatment. In Portugal, cannabis was legalized in 2018 for certain medical conditions, including chronic pain, but its use remains restricted and highly regulated.
Description
Keywords
Cannabis sativa Delta-9-tetrahidrocanabinol Canabidiol Dor crónica Sistema endocanabinoide Delta-9-tetrahydrocannabinol Cannabidiol Chronic pain Endocannabinoid system